CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Breyanzi lisocabtagene maraleucel Relapsed or refractory large B-cell lymphoma Reimburse with clinical criteria and/or conditions Complete
Trikafta elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation, 6 years and older Reimburse with clinical criteria and/or conditions Complete
Imbruvica ibrutinib Chronic lymphocytic leukemia (CLL) Reimburse with clinical criteria and/or conditions Complete
Hemgenix etranacogene dezaparvovec Hemophilia B Reimburse with clinical criteria and/or conditions Active
Remsima infliximab Crohn’s disease Reimburse with clinical criteria and/or conditions Active
Remsima infliximab Ulcerative Colitis Reimburse with clinical criteria and/or conditions Active
Livmarli maralixibat Alagille syndrome Reimburse with clinical criteria and/or conditions Active
Lorbrena lorlatinib ALK-positive locally advanced or metastatic non-small cell lung Reimburse with clinical criteria and/or conditions Complete
Libtayo cemiplimab Basal cell carcinoma Reimburse with clinical criteria and/or conditions Complete
Ngenla somatrogon Growth hormone deficiency Reimburse with clinical criteria and/or conditions Complete
Last Updated : May 12, 2024